Drug Index


Mechanism :

Efavirenz (EFV) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1). EFV activity is mediated predominantly by non-competitive inhibition of HIV-1 reverse transcriptase (RT). HIV-2 RT and human cellular DNA polymerases a, b, g, and d are not inhibited by EFV.

Indication :

  • HIV infection

Contraindications :

Contraindicated in patients with clinically significant hypersensitivity to any of its components. Avoided in pregnant women in view of potential teratogenicity. Not recommended in children less than 3 years of age.

Dosing :

Under 3 months:
Safety and efficacy not established.
Above 3 months: Oral
3.5 to 5 kg:
100 mg OD
5 to 7.5 kg:
150 mg OD
7.5 to 15 kg:
200 mg OD
15 to 20 kg:
250 mg OD
20 to 25 kg:
300 mg OD
25 to 33 kg:
350 mg OD
33 to 40 kg:
400 mg OD
>40 kg:
600 mg OD

Adverse Effect :

Psychiatric symptoms, rash, increased total cholesterol, diarrhea, depression, anxiety, headache, nausea, fatigue, dizziness, insomnia, vomiting.

Interaction :

Astemizole, Cisapride, Midazolam, Triazolam, or Ergot Derivatives: Should not be administered concurrently with astemizole, cisapride, midazolam, triazolam, or ergot derivatives because competition for CYP3A4 by efavirenz could result in inhibition of metabolism of these drugs and create the potential for serious and/or life-threatening adverse events (e.g., cardiac arrhythmias, prolonged sedation, or respiratory depression).

Voriconazole: Efavirenz should not be administered concurrently with voriconazole because it significantly decreases voriconazole plasma concentrations.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDNot dialysed. Dose as in normal renal function
HDNot dialysed. Dose as in normal renal function
HDF/High fluxNot dialysed. Dose as in normal renal function
CAV/VVHDNot dialysed. Dose as in normal renal function

Hepatic Dose :

Mild hepatic impairment: No dosage adjustment needed.
Moderate and severe hepatic impairment: Use is not recommended.
03/19/2024 00:02:29 Efavirenz
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0